Combined fluorine-18-FDG and carbon-11-methionine PET for diagnosis of tumors in lung and mediastinum

被引:1
作者
Nettelbladt, OS [1 ]
Sundin, AE
Valind, SO
Gustafsson, GR
Lamberg, K
Långström, B
Björnsson, EH
机构
[1] Univ Uppsala, Dept Lung Med, Akad Sjukhuset, Uppsala Univ PET Ctr,Dept Thorac Surg, S-75185 Uppsala, Sweden
[2] Univ Uppsala, Dept Diagnost Radiol, Akad Sjukhuset, Uppsala Univ PET Ctr,Dept Thorac Surg, S-75185 Uppsala, Sweden
关键词
PET; fluorine-18-fluorodeoxyglucose; carbon-11-methionine; lung tumor; mediastinal metastases; staging;
D O I
暂无
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
We evaluated the value of PET using F-18-fluorodeoxyglucose (FDG) and C-11-methionine, individually or in combination, to distinguish malignant from benign tumors and to identify or exclude mediastinal metastases. Methods: Seventeen patients with a tumor in the lung or mediastinum were evaluated with F-18-FDG acid C-11-methionine PET, For morphological comparison, we used CT, and all findings were confirmed by histology of surgical resection specimens (n = 16) or by cytology (n = 1), Results: All tumors were visualized equally well with both tracers, and there were no false-positive results. In 2 patients with a malignant tumor, coexisting pneumonia was correctly diagnosed as an inflammatory lesion because of its wedge-like shape. PET correctly excluded hilar invasion and mediastinal lymph node metastases in 10 of 14 patients with primary lung tumor, PET identified mediastinal metastases in 4 of 4 patients. CT failed to detect mediastinal tumor spread in 2 patients and gave a false-positive reading in 2 others. Significantly higher uptake (SUV) and transport rate (slope) values were obtained from malignant than benign lesions with both tracers, No major differences were seen in either the levels of significance or accuracy when the two tracers were compared, Slope values did not add further information to what was obtained with SUV, Density correction of SUV and slope values, to avoid the influence of surrounding air as well as tumor heterogeneity, increased these differences somewhat. Both tracers distinguished malignant from benign lesions with a 93% sensitivity and an accuracy of 89%-95%, but sensitivity improved to 100% when values from both tracers were combined, Conclusion: Fluorine-18-FDG and C-11-methionine PET visualized all tumors equally well and detected mediastinal spread better than CT, For differentiation purposes, the problems of false-positive and false-negative PET findings could not be safely overcome in a limited number of cases either by the use of both tracers, by the additional use of slope values or by lesion density correction.
引用
收藏
页码:640 / 647
页数:8
相关论文
共 40 条
[1]   CLINICAL-ASSESSMENT OF THERAPEUTIC EFFECTS ON CANCER USING F-18 2-FLUORO-2-DEOXY-D-GLUCOSE AND POSITRON EMISSION TOMOGRAPHY - PRELIMINARY-STUDY OF LUNG-CANCER [J].
ABE, Y ;
MATSUZAWA, T ;
FUJIWARA, T ;
ITOH, M ;
FUKUDA, H ;
YAMAGUCHI, K ;
KUBOTA, K ;
HATAZAWA, J ;
TADA, M ;
IDO, T ;
WATANUKI, S .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1990, 19 (04) :1005-1010
[2]  
ALBERTI W, 1995, BRIT MED J, V311, P899
[3]   CANCER STATISTICS, 1994 [J].
BORING, CC ;
SQUIRES, TS ;
TONG, T ;
MONTGOMERY, S .
CA-A CANCER JOURNAL FOR CLINICIANS, 1994, 44 (01) :7-26
[4]   CURRENT APPLICATIONS OF IMAGING PROCEDURES IN THE PATIENT WITH LUNG-CANCER [J].
BRAGG, DG .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1991, 21 (03) :847-851
[5]   PET-FDG IMAGING AND TRANSTHORACIC NEEDLE LUNG ASPIRATION BIOPSY IN EVALUATION OF PULMONARY-LESIONS - A COMPARATIVE RISK-BENEFIT ANALYSIS [J].
DEWAN, NA ;
REEB, SD ;
GUPTA, NC ;
GOBAR, LS ;
SCOTT, WJ .
CHEST, 1995, 108 (02) :441-446
[6]   DIAGNOSTIC EFFICACY OF PET-FDG IMAGING IN SOLITARY PULMONARY NODULES - POTENTIAL ROLE IN EVALUATION AND MANAGEMENT [J].
DEWAN, NA ;
GUPTA, NC ;
REDEPENNING, LS ;
PHALEN, JJ ;
FRICK, MP .
CHEST, 1993, 104 (04) :997-1002
[7]  
FUJIWARA T, 1989, J NUCL MED, V30, P33
[8]  
HATAZAWA J, 1989, J NUCL MED, V30, P1809
[9]  
HUBNER KF, 1995, CLIN NUCL MED, V20, P293
[10]   AN HISTORICAL-PERSPECTIVE OF MULTIMODALITY TREATMENT FOR RESECTABLE NONSMALL CELL LUNG-CANCER [J].
JAKLITSCH, MT ;
STRAUSS, GM ;
HEALEY, EA ;
DECAMP, MM ;
LIPTAY, MJ ;
SUGARBAKER, DJ .
LUNG CANCER, 1995, 12 :S17-S32